Which stomach rebuild after cancer surgery cuts reflux best?

NCT ID NCT06929949

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This study follows 90 adults with upper stomach or gastroesophageal junction cancer who undergo proximal gastrectomy, a surgery that removes the upper part of the stomach. Researchers compare different ways to reconnect the digestive tract, such as double-tract reconstruction or double-flap technique, to see which one leads to fewer cases of reflux esophagitis and better quality of life after surgery. Participants are observed for complications and reflux symptoms using endoscopy, barium meals, and questionnaires. The goal is to provide clearer evidence on which reconstruction method works best for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Surgical procedure: different digestive tract reconstruction methods after proximal gastrectomy
What this could lead to
If this study succeeds, it could identify which reconstruction method best reduces reflux and improves quality of life after proximal gastrectomy, guiding surgical choices for patients with upper gastric cancer.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient selection and surgeon skill. The findings may not apply to all patients or centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with upper gastric cancer (T1N0M0, T1N1M0, or T2N0M0 according to the AJCC 8th edition) and esophageal junction cancer (≤4cm in diameter).

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from over 18 to under 75 years. * Preoperative gastroscopic pathological biopsy was performed, and histologically confirmed as carcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, poorly differentiated adenocarcinoma, mixed adenocarcinoma, etc.) or adenoma. * Diagnosed with upper gastric cancer (T1N0M0, T1N1M0, or T2N0M0) or esophagogastric junction cancer with a diameter ≤4 cm based on the 8th edition of the AJCC staging system, as confirmed by CT, MRI, endoscopic ultrasound, and pathology. * Undergoing proximal gastrectomy with D2 lymphadenectomy is expected to achieve curative resection, with the remaining gastric volume required to be at least half of the pre-resection volume. * Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale. * ASA (American Society of Anesthesiology) class I to III. * The patient has adequate organ function and is capable of tolerating surgery. * Written informed consent. Exclusion Criteria: * Patients who have received preoperative radiotherapy, chemotherapy, targeted therapy, or immunotherapy. * Presence of multiple malignant tumors in the stomach. * History of upper abdominal surgery, except for laparoscopic cholecystectomy. * History of gastric surgery, except for endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) for gastric cancer. * Evidence of distant metastasis diagnosed by thoracoabdominal CT/MRI or PET-CT. * Pregnant or lactating women. * History of uncontrolled epilepsy, central nervous system disorders, or psychiatric illness. * Patients with limb disabilities or motor function impairment. * History of other malignant diseases within the past five years, except for cured skin cancer and cervical carcinoma in situ. * Clinically severe (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or higher congestive heart failure, severe arrhythmia requiring medical intervention, or myocardial infarction within the past six months. * History of stroke or cerebral hemorrhage within the past six months. * Severe, uncontrolled recurrent infections or other serious uncontrolled comorbidities. * Pulmonary function test showing FEV1 \< 50% of the predicted value. * Patients requiring emergency surgery due to tumor-related complications (e.g., bleeding, perforation, or obstruction).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma of the esophagogastric junction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.